Home » Healthcare » Pharmaceuticals » Chronic Myeloid Leukemia (CML) Treatment Market

Chronic Myeloid Leukemia (CML) Treatment Market By Type (Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy and Stem Cell Transplant), – Growth, Share, Opportunities & Competitive Analysis, 2016 -2023

Price: $4999

Published: | Report ID: 2939 | Report Format : PDF

Market Insights

The report titled “Chronic Myeloid Leukemia (CML) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2016–2023” offers strategic insights into the overall chronic myeloid leukemia (CML) treatment market, along with the market size and estimates for the duration 2013–2023. The said research study covers an in-depth analysis of multiple market segments based on types of drugs and different geographies. According to Leukemia CARE, chronic myeloid leukemia (CML) is a form of blood cancer that affects the white blood cells known as myeloid cells. It is a slowly progressing form of leukemia. In CML, the bone marrow carries out an overproduction of white cells, or granulocytes, which steadily crowd the bone marrow, ultimately interfering with normal blood cell production. There are no specific signs or symptoms that would allow a diagnosis of CML to be made. The most common signs and symptoms are caused by the bone marrow not being able to produce enough normal blood cells. CML accounts for 15% of all leukemias in adults, and approximately 8,220 new cases of CML will be diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 population.

Market experts suggest that CML is not considered curable with standard treatments, with the possible exception of stem cell transplants in a small number of younger and/or fitter patients. A new class of drugs called tyrosine kinases (TKIs) or BCR-ABL inhibitors has transformed the treatment of CML. Currently, existing BCR-ABL inhibitors form the stronghold of CML treatment, which comprises first-generation imatinib and more effective second-generation BCR-ABL inhibitors nilotinib and dasatinib, with ponatinib and bosutinib having been recently approved for market inclusion. A few published reports exhibit that nilotinib and dasatinib have higher efficacy than imatinib in first-line chronic-phase CML (CML-CP), allowing more patients to get effective results with comparatively more rapid responses related to enhanced results.

The geographical segmentation comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, and GCC countries. The market size and forecast for these segments during 2013–2023 and their CAGRs for the period 2016–2023 are provided in this report.

The chronic myeloid leukemia (CML) market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc., Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Strange Pharma SA, Otsuka Pharmaceutical Co., Ltd., and others.

Based on the type of treatment, the global chronic myeloid leukemia (CML) treatment market is segmented as follows:

  • Targeted Therapy
  • Imatinib
  • Dasatinib
  • Nilotinib
  • Bosutinib
  • Ponatinib
  • Chemotherapy
  • Radiation Therapy
  • Splenectomy
  • stem cell transplant

According to the American Cancer Society, chronic myeloid leukemia (CML) cells contain an oncogene, BCR-ABL, that isn’t found in normal cells. These genes possess the ability to make a protein, BCR-ABL, which causes CML cells to grow and reproduce at an abnormally quick rate. BCR-ABL is a type of protein known as a tyrosine kinase. Drugs known as tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the standard treatment for CML. Medical practitioners suggest that the BCR-ABL protein inhibits cell apoptosis and DNA repair, leading to genomic instability and further genetic abnormalities. Oncologists also suggest that earlier stem cell therapy was commonly used to treat CML before the launch of modern targeted therapy drugs like imatinib.

The drugs that were available earlier did not work very well, and less than half of patients survived more than five years after diagnosis. Now, targeted drugs like imatinib are the standard treatment, and transplants are being used less often. In 2015, targeted therapy accounted for the largest share of the CML treatment market due to its high efficiency, increased life expectancy, insurance coverage in developed and developing countries, and rising patient awareness related to targeted therapy. A stem cell transplant may be an option for some younger patients or patients who are intolerant to or resistant to TKIs, providing them with a better chance of a cure.

For the purpose of this study, the global chronic myeloid leukemia (CML) market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

 In the base year of 2015, North America was observed as the leading geographical region in the chronic myeloid leukemia treatment market due to the rising diagnosis rate of chronic myeloid leukemia, the market entry of novel targeted drug therapies, and an organized medical insurance environment. The American Cancer Society estimates that in 2016, about 8,220 new cases will be diagnosed with CML (4,610 in men and 3,610 in women), and about 1,070 people will die of CML (570 men and 500 women). According to a research study published in Blood Journal, the constant research carried out on chronic myelogenous leukemia (CML) treatment resulted in the 2012 USFDA approval of three drugs for the treatment of CML: bosutinib, ponatinib, and omacetaxine. This is in addition to three others approved in the last decade: imatinib, dasatinib, and nilotinib.

In 2013, it was observed that three new drugs approved had been priced at high levels: ponatinib at US$ 138,000 per year, omacetaxine at US$ 28,000 for induction and US$ 14,000 per maintenance course, and bosutinib at US$ 118,000 per year. Cancer drug prices vary widely in different geographic regions. This supports the fact that drug prices reflect geopolitical and socioeconomic dynamics of the region unrelated to the cost of drug development. In the United States, prices represent the extreme end of high prices, a reflection of a “free market economy” and the notion that “one cannot put a price on a human life,” as well as a failure of government and insurers to more actively negotiate to price for anticancer and other pharmaceuticals, in contrast to practices in other parts of the world. Overall, the CML treatment market is growing slowly, but upcoming drug approvals are expected to boost the market.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Treatment Type, 2013-2023 (Value %)
2.2 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Geography, 2015 (Value %)

Chapter 3 Global ChroniC Myeloid Leukemia (CML) Treatment Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Rising prevalence and awareness of leukemia is boosting the need for research and development
3.2.2 Incessant developments in stem cell therapy is expected to provide an effective options against drugs
3.3 Market Restraints
3.3.1 Dry drug development pipeline of CML is expected to slow down the treatment of CML
3.4 Market Opportunities
3.4.1 Future in non-invasive and efficient treatment options
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Chronic Myeloid Leukemia (CML) Treatment, by Key Players

Chapter 4 Global Chronic Myeloid Leukemia (CML) Treatment Market Analysis, By Treatment Type
4.1 Overview
4.2 Targeted Therapy
4.2.1 Imatinib
4.2.2 Dasatinib
4.2.3 Nilotinib
4.2.4 Bosutinib
4.2.5 Ponatinib
4.3 Chemotherapy
4.4 Radiation Therapy
4.5 Splenectomy
4.6 Stem Cell Transplant

Chapter 5 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Geography
5.1 Preface
5.2 North America
5.3 Europe
5.4 Asia Pacific
5.5 Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 Novartis AG
6.1.1 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.3 Teva Pharmaceuticals Industries Ltd.
6.3.1 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.4 ARIAD Pharmaceuticals, Inc.
6.4.1 ARIAD Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.5 Pfizer, Inc.
6.5.1 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.6 Hospira, Inc.
6.6.1 Hospira, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.7 Prism Pharmaceuticals
6.7.1 Prism Pharmaceuticals: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.8 Incyte Corporation
6.8.1 Incyte Corporation: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.9 Bio-Path Holdings
6.9.1 Bio-Path Holdings: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.10 Stragen Pharma SA
6.10.1 Stragen Pharma SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.11 Otsuka Pharmaceutical Co., Ltd.
6.11.1 Otsuka Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List of Figures

FIG. 1 Chronic Myeloid Leukemia (CML) Treatment Market: Research Methodology
FIG. 2 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Treatment Type, 2013-2023 (Value %)
FIG. 3 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Geography, 2015 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2015
FIG. 5 Imatinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 6 Dasatinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 7 Nilotinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 8 Bosutinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 9 Ponatinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 10 Chemotherapy Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 11 Radiation Therapy Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 12 Splenectomy Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 13 Stem Cell Transplant Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 14 North America Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)
FIG. 15 Europe Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)
FIG. 16 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)
FIG. 17 Latin America Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)
FIG. 18 Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)

List of Tables

TABLE 1 Market Competition Assessment: Chronic Myeloid Leukemia (CML) Treatment, by Key Players
TABLE 2 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Treatment Type, 2013-2023 (USD Mn)
TABLE 3 Global Targeted Therapy Market for CML Treatment, by Drugs, 2013-2023 (USD Mn)
TABLE 4 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Geography, 2013 – 2023 (USD Mn)
TABLE 5 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 6 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 ARIAD Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Hospira, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 11 Prism Pharmaceuticals: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 12 Incyte Corporation: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 13 Bio-Path Holdings: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 14 Stragen Pharma SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 15 Otsuka Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Chronic Myeloid Leukemia (CML) Treatment Market?

The market for Chronic Myeloid Leukemia (CML) Treatment Market is expected to reach USD 2,072.0 Mn in 2023.

What is the Chronic Myeloid Leukemia (CML) Treatment Market CAGR?

The Chronic Myeloid Leukemia (CML) Treatment Market is expected to see significant CAGR growth over the coming years,at 3.7%.

What is the Forecast period considered for Chronic Myeloid Leukemia (CML) Treatment Market?

The report is forecasted from 2016-2023.

What is the base year considered for Chronic Myeloid Leukemia (CML) Treatment Market?

The base year of this report is 2015.

Who are the major players in this market?

Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc. are some of the major players in the global market.

Molecular Transport Medium Market

Published:
Report ID: 35092

Angiotensin Converting Enzyme (ACE) Inhibitors Market

Published:
Report ID: 12832

Stroke Management Market

Published:
Report ID: 34872

Pulmonary Embolism Market

Published:
Report ID: 34866

Oral Macromolecular Formulation Market

Published:
Report ID: 34861

Metastatic Melanoma Cancer Diagnostics Market

Published:
Report ID: 34855

Cytomegalovirus (CMV) Infection Treatment Market

Published:
Report ID: 4417

Immune Checkpoint Inhibitors Market

Published:
Report ID: 34697

Intraosseous Devices Market

Published:
Report ID: 7197

Dermatophytic Onychomycosis Therapeutics Market

Published:
Report ID: 34653

Africa Pharmaceutical Market

Published:
Report ID: 34584

Allergic Rhinitis Treatment Market

Published:
Report ID: 34575

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN